Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with and without Sorafenib in advanced HCC
NCT02642913Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzalutamide in hepatocellular carcinoma (HCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02642913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642913.